Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used drugs, but much attention has been focused on the relationship of these drugs to cardiovascular conditions. 1 3 complicating the rehabilitation process and heavily influencing patients' clinical and pharmacological management, with an increased risk of heart failure, as well as stroke and thromboembolism. 4 Based on the CHA 2 DS 2 -VASc score, 5 AF patients with previous vascular disease (i.e. previous MI, aortic disease, and peripheral arterial disease) gain at least one added point in their thromboembolic risk assessment. Clearly, if a MI patient develops AF, such patients would be at high stroke risk, and anticoagulant therapy is recommended for stroke prevention. 6, 7 Effective stroke prevention means oral anticoagulant (OAC) therapy, whether with a vitamin K antagonist [VKA, but with good quality anticoagulation control, with a high time in a therapeutic range (.70%) to maximize efficacy and safety 8, 9 ] and more recently, with the non-VKA OACs (NOACs, previously referred to as new or novel OACs
10
). However, if NSAIDs are also used, the risk of serious bleeding is substantially increased. 11, 12 Is the association between AF and NSAIDs relevant? These data from Olsen et al. are of particular interest, and are consistent with previous reports, 13, 14 indicating an higher risk of developing AF in patients undertaking treatment with NSAIDs, in the particular setting of patients with previous MI. AF is more prevalent in the elderly, and osteoarthritis and other joint conditions are common in the elderly, leading to more common NSAID use, even out with their indications and regardless of possible side effects.
